Zeruesenay DestaRoseann S. GammalLi GongMichelle Whirl-CarrilloAditya H. GaurChonlaphat SukasemJennifer HockingsAlan MyersMarelize SwartRachel F. TyndaleCollen MasimirembwaOtito F. IwuchukwuSanika ChirwaJeffrey LennoxAndrea GaedigkTeri E. KleinDavid W. HaasFairleigh Dickinson UniversityUniversity of Texas Health Science Center at HoustonMeharry Medical CollegeIndiana University School of Medicine IndianapolisCleveland Clinic FoundationSt. Jude Children's Research HospitalUniversity of TorontoFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityMassachusetts College of Pharmacy and Health SciencesStanford UniversityVanderbilt University School of MedicineEmory University School of MedicineDivision of Clinical PharmacologyWilkins Hospital2020-01-272020-01-272019-10-01Clinical Pharmacology and Therapeutics. Vol.106, No.4 (2019), 726-73315326535000992362-s2.0-85068533591https://repository.li.mahidol.ac.th/handle/20.500.14594/51406© 2019 The Authors Clinical Pharmacology & Therapeutics  © 2019 American Society for Clinical Pharmacology and Therapeutics The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.Mahidol UniversityMedicineArticleSCOPUS10.1002/cpt.1477